Ogsiveo is a medicine used to treat adults with progressing desmoid tumours who need systemic treatment (medicines that travel through the bloodstream and affect the whole body). Desmoid tumours develop from the soft, supporting tissues of the body. They can grow rapidly and damage nearby tissues and organs. Progressing desmoid tumours are rare, and Ogsiveo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 October 2019. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2214). Ogsiveo contains the active substance nirogacestat.
Therapeutic Indication
### Therapeutic indication Ogsiveo as monotherapy is indicated for the treatment of adult patients with progressing desmoid tumours who require systemic treatment.
Therapeutic Area (MeSH)
ATC Code
L01XX81
ATC Item
xl 01 xx 81
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nirogacestat hydrobromide | N/A | Nirogacestat hydrobromide |
EMA Name
Ogsiveo
Medicine Name
Ogsiveo
Aliases
N/ANo risk management plan link.
